Tags

Type your tag names separated by a space and hit enter

Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
Eur J Surg Oncol. 1991 Feb; 17(1):51-3.EJ

Abstract

CEA, CA19-9 and CA50 are tumour-associated antigens defined by monoclonal antibodies that have been raised against adenocarcinoma cell lines, but no single antibody is specific for the detection of pancreatic malignancy. The aim of this study was to determine whether the combined use of CEA, CA19-9 and CA50 would improve diagnostic accuracy. An immunoradiometric assay was used for the detection of CEA and CA19-9 and the Delfia system for CA50. Serum was collected from 65 normal subjects, 16 with pancreatitis and 28 with pancreatic carcinoma. Of the 28 cancer patients, 24 (85%) had a CA19-9 level above 46 mu/ml, 26 (92%) had a CA50 level above 21 mu/ml and 10 (37%) had a CEA level above 7 ng/ml. Multivariant discriminant analysis on the combined antibodies showed that 96% of the malignant group, 13% of the pancreatitis group and 11% of the normal group were positive, with an overall correct classification of 91% into the three groups (multivariant discriminant analysis P less than 0.05). Thus the combined use of CEA, CA19-9 and CA50 improves diagnostic accuracy in differentiating benign from malignant disease of the pancreas.

Authors+Show Affiliations

University Department of Surgery, Bristol Royal Infirmary.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1995358

Citation

Lucarotti, M E., et al. "Clinical Evaluation of Combined Use of CEA, CA19-9 and CA50 in the Serum of Patients With Pancreatic Carcinoma." European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 17, no. 1, 1991, pp. 51-3.
Lucarotti ME, Habib NA, Kelly SB, et al. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma. Eur J Surg Oncol. 1991;17(1):51-3.
Lucarotti, M. E., Habib, N. A., Kelly, S. B., Rothnie, N. D., Nelson, O., Lindholm, L., Cooper, M. J., Wood, C. B., & Williamson, R. C. (1991). Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma. European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 17(1), 51-3.
Lucarotti ME, et al. Clinical Evaluation of Combined Use of CEA, CA19-9 and CA50 in the Serum of Patients With Pancreatic Carcinoma. Eur J Surg Oncol. 1991;17(1):51-3. PubMed PMID: 1995358.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma. AU - Lucarotti,M E, AU - Habib,N A, AU - Kelly,S B, AU - Rothnie,N D, AU - Nelson,O, AU - Lindholm,L, AU - Cooper,M J, AU - Wood,C B, AU - Williamson,R C, PY - 1991/2/1/pubmed PY - 1991/2/1/medline PY - 1991/2/1/entrez SP - 51 EP - 3 JF - European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology JO - Eur J Surg Oncol VL - 17 IS - 1 N2 - CEA, CA19-9 and CA50 are tumour-associated antigens defined by monoclonal antibodies that have been raised against adenocarcinoma cell lines, but no single antibody is specific for the detection of pancreatic malignancy. The aim of this study was to determine whether the combined use of CEA, CA19-9 and CA50 would improve diagnostic accuracy. An immunoradiometric assay was used for the detection of CEA and CA19-9 and the Delfia system for CA50. Serum was collected from 65 normal subjects, 16 with pancreatitis and 28 with pancreatic carcinoma. Of the 28 cancer patients, 24 (85%) had a CA19-9 level above 46 mu/ml, 26 (92%) had a CA50 level above 21 mu/ml and 10 (37%) had a CEA level above 7 ng/ml. Multivariant discriminant analysis on the combined antibodies showed that 96% of the malignant group, 13% of the pancreatitis group and 11% of the normal group were positive, with an overall correct classification of 91% into the three groups (multivariant discriminant analysis P less than 0.05). Thus the combined use of CEA, CA19-9 and CA50 improves diagnostic accuracy in differentiating benign from malignant disease of the pancreas. SN - 0748-7983 UR - https://www.unboundmedicine.com/medline/citation/1995358/Clinical_evaluation_of_combined_use_of_CEA_CA19_9_and_CA50_in_the_serum_of_patients_with_pancreatic_carcinoma_ L2 - https://medlineplus.gov/pancreaticcancer.html DB - PRIME DP - Unbound Medicine ER -